PD-1: programmed death-1; NK: natural killer; PD-L1: programmed cell death ligand 1; CTLA-4: cytotoxic T lymphocyte-associated protein 4; LAG-3: lymphocyte activation gene-3; MHC: major histocompatibility complex; Tex: T cell exhaustion; TIM-3: T cell immunoglobulin and mucin-domain containing protein 3; CEACAM1: carcino-embryonic antigen related cellular adhesion molecule 1; TIGIT: T cell immunoreceptor with Ig and ITIM domains.
Declarations
Author contributions
QB, HC, and SW: Writing—original draft. ZT and HT: Conceptualization, Supervision, Writing—review & editing. All authors read and approved the submitted version.
Conflicts of interest
The authors declare that there are no conflicts of interest.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Sutherland AR, Parlekar B, Livingstone DW, Medina AX, Bernhard W, García TH, et al. Antibody-targeted T cells and natural killer cells for cancer immunotherapy.J Nanobiotechnology. 2024;22:640. [DOI] [PubMed] [PMC]
Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy.Nat Rev Immunol. 2020;20:75–6. [DOI] [PubMed]
Peng M, Lu X, Guo J, Yin X, Zhang J, Li X, et al. A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy.Biomark Res. 2024;12:151. [DOI] [PubMed] [PMC]
Ribas A, Haining WN, Schumacher TNM. When Cancer Cells Become the Enablers of an Antitumor Immune Response.Cancer Discov. 2022;12:2244–8. [DOI] [PubMed]
Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.Mol Cancer. 2019;18:155. [DOI] [PubMed] [PMC]
Serrano García L, Jávega B, Llombart Cussac A, Gión M, Pérez-García JM, Cortés J, et al. Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.Front Immunol. 2024;15:1513421. [DOI] [PubMed] [PMC]
Freeman JQ, Huo D, Shubeck SP, Chen N, Yarlagadda SR, Nanda R, et al. Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US.JAMA Netw Open. 2025;8:e2460243. [DOI] [PubMed] [PMC]
Rapoport BL, Nayler S, Mlecnik B, Smit T, Heyman L, Bouquet I, et al. Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+, CD8+, and Immunoscore Are Associated with a Pathological Complete Response.Cancers (Basel). 2022;14:2525. [DOI] [PubMed] [PMC]
Ge MJ, Xu KL, Xu T, Tang YN, Li ZY, Yan ZL, et al. Expression and Significance of PD-1, TIM-3 and VISTA on T Cell of Acute Myeloid Leukemia Patients.Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020;28:748–52. Chinese. [DOI] [PubMed]
Zhang T, Liu H, Jiao L, Zhang Z, He J, Li L, et al. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.J Immunother Cancer. 2022;10:e004114. [DOI] [PubMed] [PMC]
Huang Y, Zhong M, Gao R, Wang X, Zhong S, Zhong L, et al. BET Inhibitor JQ1 Selectively Reduce Tregs by Upregulating STAT3 and Suppressing PD-1 Expression in Patients with Multiple Myeloma.Adv Biol (Weinh). 2024;8:2300640. [DOI] [PubMed]
Rappaport AR, Kyi C, Lane M, Hart MG, Johnson ML, Henick BS, et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.Nat Med. 2024;30:1013–22. [DOI] [PubMed]
Alemohammad H, Najafzadeh B, Asadzadeh Z, Baghbanzadeh A, Ghorbaninezhad F, Najafzadeh A, et al. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.Biomed Pharmacother. 2022;146:112516. [DOI] [PubMed]
Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, et al. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.Cancer Cell. 2020;38:685–700.e8. [DOI] [PubMed]
Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1/PD-L1 in cancers.Mol Cancer. 2024;23:108. [DOI] [PubMed] [PMC]
Chikuma S. CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation.Curr Top Microbiol Immunol. 2017;410:99–126. [DOI] [PubMed]
Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, et al. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.Nat Commun. 2022;13:1970. [DOI] [PubMed] [PMC]
Maruhashi T, Sugiura D, Okazaki IM, Shimizu K, Maeda TK, Ikubo J, et al. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity.Immunity. 2022;55:912–24.e8. [DOI] [PubMed]
Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy.Nat Commun. 2021;12:832. [DOI] [PubMed] [PMC]
Fu Z, Liu H, Wang L, Yu C, Yang Y, Feng M, et al. A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT.Acta Pharm Sin B. 2021;11:3925–34. [DOI] [PubMed] [PMC]
Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion.Nat Rev Immunol. 2015;15:486–99. [DOI] [PubMed] [PMC]
Philip M, Schietinger A. CD8+ T cell differentiation and dysfunction in cancer.Nat Rev Immunol. 2022;22:209–23. [DOI] [PubMed] [PMC]
Voorwerk L, Isaeva OI, Horlings HM, Balduzzi S, Chelushkin M, Bakker NAM, et al. PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.Nat Cancer. 2023;4:535–49. [DOI] [PubMed] [PMC]
Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, et al. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.Nat Commun. 2020;11:3584. [DOI] [PubMed] [PMC]
Li D, Rudloff U. Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers.Expert Opin Emerg Drugs. 2025;30:109–47. [DOI] [PubMed] [PMC]
Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.Cancer Discov. 2018;8:1069–86. [DOI] [PubMed]
El-Houseini ME, Arafat MS, El-Husseiny AM, Kasem IM, Kamel MM, El-Habashy AH, et al. Biological and molecular studies on specific immune cells treated with checkpoint inhibitors for the thera-personal approach of breast cancer patients (ex-vivo study).Oncol Res. 2021;29:319–29. [DOI] [PubMed] [PMC]
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy.Nat Med. 2018;24:541–50. [DOI] [PubMed] [PMC]
Ettl T, Grube M, Schulz D, Bauer RJ. Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers.Cancers (Basel). 2022;14:4985. [DOI] [PubMed] [PMC]
Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway.Nat Rev Immunol. 2018;18:153–67. [DOI] [PubMed]
Lawson NL, Dix CI, Scorer PW, Stubbs CJ, Wong E, Hutchinson L, et al. Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies.Mod Pathol. 2020;33:518–30. [DOI] [PubMed] [PMC]
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al.; KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.Lancet. 2020;396:1817–28. [DOI] [PubMed]
Yu Y, Jin X, Zhu X, Xu Y, Si W, Zhao J. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.Front Immunol. 2023;14:1206689. [DOI] [PubMed] [PMC]
Xie W, Medeiros LJ, Li S, Yin CC, Khoury JD, Xu J. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.Curr Hematol Malig Rep. 2020;15:372–81. [DOI] [PubMed]
Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.Front Oncol. 2018;8:86. [DOI] [PubMed] [PMC]
Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, et al. Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.Mol Cancer Ther. 2018;17:671–6. [DOI] [PubMed] [PMC]
Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.Nat Immunol. 2019;20:1425–34. [DOI] [PubMed]
Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, et al. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.Nat Med. 2023;29:2814–24. [DOI] [PubMed] [PMC]
Autio KA, Klebanoff CA, Schaer D, Kauh JSW, Slovin SF, Adamow M, et al. Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study.Clin Cancer Res. 2020;26:5609–20. [DOI] [PubMed] [PMC]
Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields CE, Niknafs N, Yen RC, et al. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.Cell. 2017;171:1284–300.e21. [DOI] [PubMed] [PMC]
Falahi F, van Kruchten M, Martinet N, Hospers GA, Rots MG. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.Breast Cancer Res. 2014;16:412. [DOI] [PubMed] [PMC]
Ma Z, Hu J, Wu F, Liu N, Su Q. Respiratory adverse effects in patients treated with immune checkpoint inhibitors in combination with radiotherapy: a systematic review and meta-analysis.Radiat Oncol. 2024;19:134. [DOI] [PubMed] [PMC]
Vo MC, Jung SH, Chu TH, Lee HJ, Lakshmi TJ, Park HS, et al. Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma.Front Immunol. 2018;9:1370. [DOI] [PubMed] [PMC]
Dufva O, Pölönen P, Brück O, Keränen MAI, Klievink J, Mehtonen J, et al. Immunogenomic Landscape of Hematological Malignancies.Cancer Cell. 2020;38:380–99.e13. [DOI] [PubMed]
Elia G, Ferrari SM, Galdiero MR, Ragusa F, Paparo SR, Ruffilli I, et al. New insight in endocrine-related adverse events associated to immune checkpoint blockade.Best Pract Res Clin Endocrinol Metab. 2020;34:101370. [DOI] [PubMed]
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.N Engl J Med. 2019;381:1535–46. [DOI] [PubMed]
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.J Clin Oncol. 2022;40:127–37. [DOI] [PubMed] [PMC]
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al.; KEYNOTE-189 Investigators. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.N Engl J Med. 2018;378:2078–92. [DOI] [PubMed]
Chu X, Tian W, Ning J, Zhou R. Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis.J Natl Cancer Inst. 2024;116:1571–86. [DOI] [PubMed]
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al.; IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.N Engl J Med. 2018;379:2108–21. [DOI] [PubMed]
Garcia-Marquez MA, Thelen M, Reinke S, Keller D, Wennhold K, Lehmann J, et al. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma.Leukemia. 2022;36:760–71. [DOI] [PubMed] [PMC]
Allen PB, Savas H, Evens AM, Advani RH, Palmer B, Pro B, et al. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.Blood. 2021;137:1318–26. [DOI] [PubMed] [PMC]
Zhong M, Gao R, Zhao R, Huang Y, Chen C, Li K, et al. BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.Cell Death Dis. 2022;13:671. [DOI] [PubMed] [PMC]
Sato T, Sugiyama D, Koseki J, Kojima Y, Hattori S, Sone K, et al. Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages.JCI Insight. 2025;10:e178146. [DOI] [PubMed] [PMC]
Barbato A, Giallongo C, Giallongo S, Romano A, Scandura G, Concetta S, et al. Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma.Cell Prolif. 2023;56:e13388. [DOI] [PubMed] [PMC]
Zhu Y, Zhou Z, Du X, Lin X, Liang ZM, Chen S, et al. Cancer cell-derived arginine fuels polyamine biosynthesis in tumor-associated macrophages to promote immune evasion.Cancer Cell. 2025;43:1045–60.e7. [DOI] [PubMed]
Li X, Wenes M, Romero P, Huang SC, Fendt SM, Ho PC. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.Nat Rev Clin Oncol. 2019;16:425–41. [DOI] [PubMed]
Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation.Nat Commun. 2017;8:1136. [DOI] [PubMed] [PMC]
Ricciuti B, Lamberti G, Puchala SR, Mahadevan NR, Lin JR, Alessi JV, et al. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.J Clin Oncol. 2024;42:1311–21. [DOI] [PubMed] [PMC]
Sun W, Hu S, Wang X. Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies.Cancer Commun (Lond). 2024;44:1071–97. [DOI] [PubMed] [PMC]
Hatic H, Sampat D, Goyal G. Immune checkpoint inhibitors in lymphoma: challenges and opportunities.Ann Transl Med. 2021;9:1037. [DOI] [PubMed] [PMC]
Ennishi D, Takata K, Béguelin W, Duns G, Mottok A, Farinha P, et al. Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.Cancer Discov. 2019;9:546–63. [DOI] [PubMed]
Ballhausen A, Ben Hamza A, Welters C, Dietze K, Bullinger L, Rahn HP, et al. Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma.Cancer Immunol Immunother. 2023;72:515–21. [DOI] [PubMed] [PMC]
Roemer MGM, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.J Clin Oncol. 2016;34:2690–7. [DOI] [PubMed] [PMC]
Spasevska I, Sharma A, Steen CB, Josefsson SE, Blaker YN, Kolstad A, et al. Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma.Blood Adv. 2023;7:7216–30. [DOI] [PubMed] [PMC]
Bergamini A, Tassi E, Wignall J, Bocciolone L, Candiani M, Potenza A, et al. 1900P - Activated effector T cells co-expressing multiple inhibitory receptors (IRs) are enriched in the tumor immune microenvironment in high grade serous ovarian cancer (HGSOC).Ann Oncol. 2019;30:v770. [DOI]
Ho CI, Gopal AK, Ujjani CS, Lynch RC, Poh C, Voutsinas JM, et al. Pembrolizumab with Rituximab in Relapsed/Refractory Follicular Lymphoma and Diffuse Large B Cell Lymphoma.Blood. 2023;142:6144. [DOI]
Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.Blood. 2017;130:267–70. [DOI] [PubMed] [PMC]
Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.J Clin Oncol. 2019;37:3291–9. [DOI] [PubMed] [PMC]
Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al.; KEYNOTE-087. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.J Clin Oncol. 2017;35:2125–32. [DOI] [PubMed] [PMC]
Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.Blood. 2011;117:4501–10. [DOI] [PubMed] [PMC]
Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.Cell Stem Cell. 2010;7:708–17. [DOI] [PubMed]
Xu S, Zhang N, Rinne ML, Sun H, Stein AM. Sabatolimab (MBG453) model-informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors.CPT Pharmacometrics Syst Pharmacol. 2023;12:1653–65. [DOI] [PubMed] [PMC]
Gonçalves Silva I, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Bardelli M, et al. The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells.EBioMedicine. 2017;22:44–57. [DOI] [PubMed] [PMC]
Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, et al.; Leukemia and Lymphoma Society Blood Cancer Research Partnership. Ipilimumab for Patients with Relapse after Allogeneic Transplantation.N Engl J Med. 2016;375:143–53. [DOI] [PubMed] [PMC]
Chai J, Choudhuri J, Wang Q, Fang Y, Shi Y, Kamel J, et al. Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.Leuk Lymphoma. 2023;64:1662–72. [DOI] [PubMed]
Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, et al. Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy.Blood. 2020;136:29–31. [DOI]
Moscvin M, Evans B, Bianchi G. Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions.J Cancer Metastasis Treat. 2023;9:17. [DOI] [PubMed] [PMC]
Mandavkar AA, Padakanti SSN, Gupta S, Akram S, Jaffar N, Chauhan J, et al. Emerging therapies in Multiple Myeloma: Leveraging immune checkpoint inhibitors for improved outcomes.Hum Antibodies. 2025;33:10–24. [DOI] [PubMed]
Liu ZY, Meng NH, Cao PP, Jia Y, Wang H, Zhang YH, et al. Bone marrow-derived mesenchymal stem cells inhibit NK cell function via Tim-3/galectin-9 in multiple myeloma patients.Clin Transl Med. 2023;13:e1224. [DOI] [PubMed] [PMC]
Davis LN, Walker ZJ, Reiman LT, Parzych SE, Stevens BM, Jordan CT, et al. MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance.Clin Cancer Res. 2024;30:3023–35. [DOI] [PubMed] [PMC]
Fu R, Deng L, Liu Z, Liu H, Shao Z. Study of Bone Marrow Mesenchymal Stem Cells Regulating NK Cells Function through Tigit/ CD226 in Patients with Multiple Myeloma.Blood. 2021;138:2685. [DOI]
Chu X, Tian W, Wang Z, Zhang J, Zhou R. Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.Mol Cancer. 2023;22:93. [DOI] [PubMed] [PMC]
Richard S, Lesokhin AM, Paul B, Kaufman JL, Pianko M, Biran N, et al. Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial.Nat Cancer. 2024;5:1459–64. [DOI] [PubMed] [PMC]
Lejeune M, Köse MC, Jassin M, Gou MJ, Herbet A, Duray E, et al. Integrative Analysis of Proteomics and Transcriptomics Reveals Endothelin Receptor B as Novel Single Target and Identifies New Combinatorial Targets for Multiple Myeloma.Hemasphere. 2023;7:e901. [DOI] [PubMed] [PMC]
Liu C, Xie J, Lin B, Tian W, Wu Y, Xin S, et al. Pan-Cancer Single-Cell and Spatial-Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy.Adv Sci (Weinh). 2024;11:2401061. [DOI] [PubMed] [PMC]
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al.; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer.N Engl J Med. 2020;382:810–21. [DOI] [PubMed]
Zou Y, Ye F, Kong Y, Hu X, Deng X, Xie J, et al. The Single-Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer.Adv Sci (Weinh). 2023;10:2203699. [DOI] [PubMed] [PMC]
Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.Lancet Oncol. 2020;21:1283–95. [DOI] [PubMed]
Goldberg J, Pastorello RG, Vallius T, Davis J, Cui YX, Agudo J, et al. The Immunology of Hormone Receptor Positive Breast Cancer.Front Immunol. 2021;12:674192. [DOI] [PubMed] [PMC]
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al.; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.N Engl J Med. 2022;386:556–67. [DOI] [PubMed]
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, et al.; IMpassion131 investigators. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.Ann Oncol. 2021;32:994–1004. [DOI] [PubMed]
Triulzi T, Forte L, Regondi V, Di Modica M, Ghirelli C, Carcangiu ML, et al. HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy.Oncoimmunology. 2019;8:e1512942. [DOI] [PubMed] [PMC]
Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, Chic N, et al. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer.NPJ Precis Oncol. 2021;5:23. [DOI] [PubMed] [PMC]
Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, et al.; International Breast Cancer Study Group and the Breast International Group. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.Lancet Oncol. 2019;20:371–82. [DOI] [PubMed]
Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.Nature. 2021;600:727–30. [DOI] [PubMed] [PMC]
Tolaney SM, Jerusalem G, Salgado R, Liu X, Chen T, Zhang H, et al. 133TiP A phase II trial of nivolumab + palbociclib + anastrozole in postmenopausal women with ER+/HER2– primary breast cancer: CheckMate 7A8.Ann Oncol. 2020;31:S60. [DOI]
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2– Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.J Clin Oncol. 2017;35:2875–84. [DOI] [PubMed]
Zou Y, Hu X, Zheng S, Yang A, Li X, Tang H, et al. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.EBioMedicine. 2021;63:103137. [DOI] [PubMed] [PMC]
Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, et al. Immunological differences between primary and metastatic breast cancer.Ann Oncol. 2018;29:2232–9. [DOI] [PubMed]
Hurvitz S, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03.Cancer Res. 2022;82:GS3-01. [DOI]
Ramadori P, Li X, Heikenwalder M. PKCλ/ι Loss Induces Metabolic Reprogramming in Liver Cancer: Hitting Two Birds with One Stone?Cancer Cell. 2020;38:152–4. [DOI] [PubMed]
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.Cell Mol Immunol. 2020;17:807–21. [DOI] [PubMed] [PMC]
Xie D, Tian Y, Hu D, Wang Y, Yang Y, Zhou B, et al. Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy.Signal Transduct Target Ther. 2023;8:436. [DOI] [PubMed] [PMC]
Liu D. CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy.J Hematol Oncol. 2019;12:113. [DOI] [PubMed] [PMC]
Carloni R, Rizzo A, Ricci AD, Frega G, Federico AD, Palloni A, et al. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?Future Oncol. 2022;18:1023–34. [DOI] [PubMed]
Goldstein DA, Ginsberg GM, Hofnung-Gabbay D, De Abreu Lourenco R, Loong HH, Goh BC, et al. Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors.JAMA Netw Open. 2023;6:e230490. [DOI] [PubMed] [PMC]
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Cell. 2017;168:707–23. [DOI] [PubMed] [PMC]
Xiang X, Li Y, Yang X, Guo W, Zhou P. Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis.BMJ Open. 2022;12:e058692. [DOI] [PubMed] [PMC]
Verma C, Eremin JM, Robins A, Bennett AJ, Cowley GP, El-Sheemy MA, et al. Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC.J Transl Med. 2013;11:16. [DOI] [PubMed] [PMC]
Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors.Br J Cancer. 2018;118:9–16. [DOI] [PubMed] [PMC]
Wang X, Zhang Q, Cao X. Reversing epigenetic repression of transposable elements for improving tumor immunogenicity.Cancer Commun (Lond). 2022;42:266–8. [DOI] [PubMed] [PMC]
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.J Clin Oncol. 2021;39:4073–126. [DOI] [PubMed]
Verheijden RJ, van Eijs MJM, May AM, van Wijk F, Suijkerbuijk KPM. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance.NPJ Precis Oncol. 2023;7:41. [DOI] [PubMed] [PMC]
Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health.Nat Rev Clin Oncol. 2018;15:382–96. [DOI] [PubMed]
Cha HR, Lee JH, Ponnazhagan S. Revisiting Immunotherapy: A Focus on Prostate Cancer.Cancer Res. 2020;80:1615–23. [DOI] [PubMed] [PMC]
Wu ZH, Li N, Gao ZZ, Chen G, Nie L, Zhou YQ, et al. Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy.Cancers (Basel). 2022;14:4964. [DOI] [PubMed] [PMC]
Omstead AN, Paskewicz M, Gorbunova A, Zheng P, Salvitti MS, Mansoor R, et al. CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model.Carcinogenesis. 2022;43:842–50. [DOI] [PubMed]
Zhou Y, Li J, Ying J. Anti-PD-1/L1 antibody plus anti-VEGF antibody vs. plus VEGFR-targeted TKI as first-line therapy for unresectable hepatocellular carcinoma: a network meta-analysis.Explor Target Antitumor Ther. 2024;5:568–80. [DOI] [PubMed] [PMC]
Zhong L, Wu D, Peng W, Sheng H, Xiao Y, Zhang X, et al. Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma.Front Oncol. 2021;11:686621. [DOI] [PubMed] [PMC]
Guo Z, Liu Y, Chen D, Sun Y, Li D, Meng Y, et al. Targeting regulated cell death: Apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis in anticancer immunity.J Transl Int Med. 2025;13:10–32. [DOI] [PubMed] [PMC]
Liu X, Zhao Y, Wu X, Liu Z, Liu X. A novel strategy to fuel cancer immunotherapy: targeting glucose metabolism to remodel the tumor microenvironment.Front Oncol. 2022;12:931104. [DOI] [PubMed] [PMC]
Leone RD, Powell JD. Metabolism of immune cells in cancer.Nat Rev Cancer. 2020;20:516–31. [DOI] [PubMed] [PMC]
Gao S, Miao X, Liu J. CRISPR Technology in Tumor Immunotherapy: Application, limitations, and Improvement Methods.Trans Mater Biotechnol Life Sci. 2024;3:587–93. [DOI]
Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma.Nature. 2022;611:155–60. [DOI] [PubMed] [PMC]
Yin N, Li X, Zhang X, Xue S, Cao Y, Niedermann G, et al. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.Signal Transduct Target Ther. 2024;9:126. [DOI] [PubMed] [PMC]
Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey.Nat Med. 2019;25:1341–55. [DOI] [PubMed]
Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges.Nat Rev Clin Oncol. 2023;20:160–77. [DOI] [PubMed]
